MetrionAIIntelligence

Sign in Register

Home Watchlist Market News High Impact News Market Movers Screener Portfolio Calculators Heatmap Compare Calendars Crypto Forex Macro Maps

Research Tools

Financial Analysis Analyst Estimates Insider Trading Market Guide Trading Ideas Charts

Financial Analysis

Highlights Income Statement Balance Sheet Cash Flow Multiples Profitability

Loading market dashboard

My Watchlist

Sign in to track securities

Create an account to keep a persistent watchlist.

Home High Impact News Market Movers

Back to markets

globenewswire.com/March 18, 2026 at 7:41 AMARTL

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13's clinical potential into ophthalmology

Open original source